Imagine detecting Alzheimer’s, catching cancer recurrence, or flagging a heart attack risk — all from a single vial of blood. That’s no longer a distant vision; it’s the fastest-moving reality in diagnostics today. The Blood-Based Biomarkers Market is valued at USD 8.50 billion in 2025 and is on track to nearly double to USD 18.50 billion by 2034, expanding at a compelling 9.0% CAGR. For investors, diagnostics companies, and healthcare strategists, this is a market you cannot afford to watch from the sidelines.
The Forces Powering This Growth Story
Three converging trends are propelling this market forward. First, the global cancer burden is climbing fast — the International Agency for Research on Cancer expects cases to nearly double from 20 million in 2022 to 35 million by 2050, fueling explosive demand for liquid biopsy and circulating tumor DNA testing. Second, an aging world population is driving unprecedented need for non-invasive neurological diagnostics. Third, and most transformative, is the 2025 wave of regulatory clearances that finally brought Alzheimer’s blood testing into mainstream clinical practice.
Genetic biomarkers currently lead the pack with a 41% market share, oncology dominates applications at 39%, immunoassays hold 36% of the technology landscape, and hospital and diagnostic laboratories capture 48% of end-user demand. North America commands the largest regional share at 44%, while Asia-Pacific is emerging as the fastest-growing region, powered by expanding healthcare access across China, Japan, and India.
Alzheimer’s Testing: The Category Redefining the Market
Nothing illustrates this market’s momentum better than the rise of the Blood-Based Biomarker for Alzheimer’s Disease Diagnostics Market. In May 2025, Fujirebio secured the first-ever FDA clearance for a blood-based test to aid Alzheimer’s diagnosis — its Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio assay. Labcorp scaled it nationwide within three months. Roche followed in October 2025 with FDA clearance for its Elecsys pTau181 test, extending blood-based diagnosis into primary care. The Alzheimer’s Association cemented this shift with its first-ever clinical practice guideline endorsing these tests for triage — and in select patients, as a substitute for costly PET imaging or spinal taps.
Who’s Winning the Race in Neurology?
So what is Fujirebio’s vision for the future of blood-based biomarkers for neurological disorders compared to its competitors? Fujirebio isn’t just chasing approvals — it’s building an ecosystem. Its December 2024 partnership with Eisai for joint research into phosphorylated tau diagnostics signals a long-term ambition to pair blood tests directly with disease-modifying therapies, not just stand-alone diagnosis.
How is Fujirebio positioned within the neurodegenerative disease diagnostics space, and how does this compare with key competitors in terms of biomarkers, technologies, and partnerships? Fujirebio holds the first-mover advantage as the only company with FDA clearance for an amyloid pathology blood test, giving it unmatched clinical credibility. Roche is closing the gap fast, using its Elecsys platform and earlier Breakthrough Device Designation (with Eli Lilly) to push deeper into primary-care settings — territory Fujirebio hasn’t fully captured yet. Quanterix, meanwhile, competes on raw sensitivity with its ultra-sensitive single-molecule detection technology, while its collaboration with Biogen and Beckman Coulter shows that partnerships — not solo innovation — are now the currency of competitive advantage in this space.
And where does Thermo Fisher Scientific’s use of biomarkers in neurodegenerative diseases fit into this race? Rather than chasing individual test clearances, Thermo Fisher plays the enabler role — its mass spectrometry and proteomics platforms power the discovery and validation work behind the scenes, feeding the pipeline that produces tomorrow’s clinically approved neurological tests. It’s a quieter, infrastructure-first strategy, but no less essential to the market’s forward momentum.
The Bottom Line for Decision-Makers
With disease burden rising, regulatory clearances accelerating, and AI-powered multi-biomarker panels on the horizon, this market rewards those who move early. Whether you’re a diagnostics developer, investor, or healthcare strategist, understanding where the next wave of clearances, partnerships, and regional expansion will happen is critical to capturing your share of this USD 18.50 billion opportunity.
Want the full competitive breakdown, company-level strategies, and country-by-country forecasts through 2034? Unlock the complete Blood Based Biomarkers Market report today and get ahead of the diagnostics revolution before your competitors do.
Latest Reports Offered by Delveinsight
aids dementia market | vascular imaging devices market | benign prostatic hyperplasia market | acoustic neuroma market | adhd market | amyotrophic lateral sclerosis market | gout disease treatment market | metastatic pancreatic cancer market | restrictive cardiomyopathy market | stereotactic surgery devices market | allergic asthma therapeutics market | axial spondyloarthritis market | leber congenital amaurosis market | spinal fusion devices market | surgical robotic system market | us healthcare outlook report | absssi market | androgenetic alopecia market | coronary stents market | embolotherapy market | endoscopes market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk